MX2012013130A - Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. - Google Patents

Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.

Info

Publication number
MX2012013130A
MX2012013130A MX2012013130A MX2012013130A MX2012013130A MX 2012013130 A MX2012013130 A MX 2012013130A MX 2012013130 A MX2012013130 A MX 2012013130A MX 2012013130 A MX2012013130 A MX 2012013130A MX 2012013130 A MX2012013130 A MX 2012013130A
Authority
MX
Mexico
Prior art keywords
heterocyclic compounds
nitrogen heterocyclic
compounds useful
pde10 inhibitors
pde10
Prior art date
Application number
MX2012013130A
Other languages
English (en)
Inventor
Qingyian Liu
Michael J Frohn
Robert M Rzasa
Wenge Zhong
Jennifer R Allen
Jian J Chen
Shannon Rumfelt
Alexander J Pickrell
Essa Hu Harrington
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44278966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012013130(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2012013130A publication Critical patent/MX2012013130A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Se describen compuestos heterocíclicos de nitrógeno insaturados de la fórmula (I) (Ver Formula) (I), como se definen en la especificación, composiciones que los contienen, y procesos para preparar tales compuestos. También se proporcionan en la presente métodos para tratar trastornos o enfermedades tratables por inhibición de PDE10, tales como obesidad, enfermedad de Huntington, diabetes no dependiente a insulina, esquizofrenia, trastorno bipolar, trastorno obsesivo compulsivo, y similares.
MX2012013130A 2010-05-13 2011-05-11 Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. MX2012013130A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33452510P 2010-05-13 2010-05-13
PCT/US2011/036148 WO2011143365A1 (en) 2010-05-13 2011-05-11 Nitrogen heterocyclic compounds useful as pde10 inhibitors

Publications (1)

Publication Number Publication Date
MX2012013130A true MX2012013130A (es) 2013-04-11

Family

ID=44278966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013130A MX2012013130A (es) 2010-05-13 2011-05-11 Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.

Country Status (25)

Country Link
US (3) US8957073B2 (es)
EP (1) EP2569300A1 (es)
JP (1) JP5702855B2 (es)
KR (1) KR101564806B1 (es)
CN (1) CN103221404B (es)
AR (1) AR081627A1 (es)
AU (1) AU2011253057B2 (es)
BR (1) BR112012029026A2 (es)
CA (1) CA2798490A1 (es)
CL (1) CL2012003178A1 (es)
CO (1) CO6630189A2 (es)
CR (1) CR20120635A (es)
EA (1) EA201291236A1 (es)
IL (1) IL222898A (es)
MA (1) MA34300B1 (es)
MX (1) MX2012013130A (es)
NZ (1) NZ603876A (es)
PE (1) PE20130576A1 (es)
SG (1) SG185515A1 (es)
TN (1) TN2012000530A1 (es)
TW (1) TW201206902A (es)
UA (1) UA109438C2 (es)
UY (1) UY33382A (es)
WO (1) WO2011143365A1 (es)
ZA (1) ZA201208510B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2569302A1 (en) * 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
EA201291236A1 (ru) * 2010-05-13 2013-11-29 Эмджен Инк. Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
SG192839A1 (en) 2011-02-18 2013-09-30 Allergan Inc Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
HUE059230T2 (hu) 2011-06-10 2022-10-28 Merck Patent Gmbh Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására
US8623860B2 (en) * 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
BR112014027805A2 (pt) * 2012-05-09 2017-06-27 Zoetis Llc derivados de azetidina como agentes antiparasitários
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20150374687A1 (en) * 2013-02-07 2015-12-31 Merck Patent Gmbh Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
AU2015217073B2 (en) 2014-02-13 2019-08-22 Incyte Holdings Corporation Cyclopropylamines as LSD1 inhibitors
HUE045725T2 (hu) 2014-02-13 2020-01-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20170245A1 (es) * 2014-02-14 2017-03-30 Takeda Pharmaceuticals Co Pirazinas moduladoras de gpr 6
CN104016911A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3,5-二溴吡啶的合成方法
CN104016909B (zh) * 2014-04-03 2016-04-20 定陶县友帮化工有限公司 一种2-氨基-3-溴-5-氯吡啶的合成方法
NZ726874A (en) * 2014-05-19 2018-03-23 Merial Inc Anthelmintic compounds
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
US9855249B2 (en) 2014-10-02 2018-01-02 Flatley Discovery Lab, Llc Isoxazole compounds and methods for the treatment of cystic fibrosis
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
EP3445339B1 (en) 2016-04-22 2023-08-23 Incyte Corporation Formulations of an lsd1 inhibitor
WO2017205425A1 (en) * 2016-05-24 2017-11-30 President And Fellows Of Harvard College Compounds for organic light emitting diode materials
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
FI3555064T3 (fi) * 2016-12-16 2023-01-31 Glp-1-reseptoriagonisteja ja niiden käyttöjä
LT3571193T (lt) 2017-01-23 2022-02-10 Cadent Therapeutics, Inc. Kalio kanalo moduliatoriai
CN106957300A (zh) * 2017-04-12 2017-07-18 苏州汉德创宏生化科技有限公司 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法
EP3700935A4 (en) * 2017-10-25 2021-08-04 University Of South Florida INGREDIENT-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
MX2020004283A (es) 2017-10-27 2021-10-21 Boehringer Ingelheim Int Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CN109956931B (zh) * 2017-12-26 2021-07-16 迈第康(上海)生物医药科技有限公司 四氢吡咯类化合物、其制备方法、药物组合物及用途
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
MX2020013624A (es) * 2018-06-15 2022-08-11 Pfizer Agonistas del receptor glp-1 y usos de los mismos.
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
UY38394A (es) 2018-10-02 2020-04-30 Syngenta Participations Ag Compuestos de benceno y azina-amida activos como plaguicidas
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
PE20211871A1 (es) 2018-11-22 2021-09-21 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
EP3888848A4 (en) 2018-11-26 2022-08-03 Kyocera Corporation GAS NOZZLE, METHOD OF MAKING A GAS NOZZLE AND PLASMA TREATMENT DEVICE
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TW202102489A (zh) 2019-03-29 2021-01-16 瑞士商先正達農作物保護公司 殺有害生物活性之二𠯤-醯胺化合物
CN113661165A (zh) 2019-04-05 2021-11-16 先正达农作物保护股份公司 杀有害生物活性的二嗪-酰胺化合物
CA3131861A1 (en) 2019-04-11 2020-10-15 Jurgen Harry Schaetzer Pesticidally active diazine-amide compounds
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
MA55627A (fr) * 2019-04-12 2022-02-16 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
WO2021037614A1 (en) 2019-08-23 2021-03-04 Syngenta Crop Protection Ag Pesticidally active pyrazine-amide compounds
JP2022547707A (ja) * 2019-09-12 2022-11-15 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
EP4059929A4 (en) * 2019-11-15 2023-11-01 Ildong Pharmaceutical Co., Ltd. GLP-1 RECEPTOR AGONIST AND ITS USE
AU2021237185B2 (en) * 2020-03-18 2023-11-30 Lg Chem, Ltd. GLP-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
CN115279750A (zh) * 2020-03-18 2022-11-01 株式会社Lg化学 Glp-1受体激动剂、包含该激动剂的药物组合物及其制备方法
CN116507282A (zh) * 2020-11-19 2023-07-28 睿升公司 放射性药物酮和阿尔茨海默病、认知障碍与其他脑代谢改变病症中的双示踪剂成像
WO2022258481A1 (en) 2021-06-09 2022-12-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
IL308122A (en) * 2021-06-16 2023-12-01 Celgene Corp Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AR036608A1 (es) * 2001-09-24 2004-09-22 Bayer Corp Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
PT1511710E (pt) * 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
EP1551811A1 (en) * 2002-10-17 2005-07-13 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
GB0325287D0 (en) * 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
PE20060241A1 (es) * 2004-05-18 2006-04-01 Schering Corp 2-quinolil-oxazoles sustituidos como inhibidores de pde4
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20070072908A1 (en) * 2005-06-08 2007-03-29 Japan Tobacco Inc. Heterocyclic compounds
WO2007076104A1 (en) * 2005-12-23 2007-07-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
BRPI0707223A2 (pt) * 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
US8003649B2 (en) 2007-12-21 2011-08-23 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
MX2011011964A (es) * 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
AU2010289397B2 (en) * 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
EP2479165B1 (en) 2009-09-16 2017-10-25 Astellas Pharma Inc. Glycine compound
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
EA201291236A1 (ru) * 2010-05-13 2013-11-29 Эмджен Инк. Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Also Published As

Publication number Publication date
TN2012000530A1 (en) 2014-04-01
WO2011143365A1 (en) 2011-11-17
US8957073B2 (en) 2015-02-17
IL222898A (en) 2015-11-30
AR081627A1 (es) 2012-10-10
EP2569300A1 (en) 2013-03-20
CR20120635A (es) 2013-01-30
UY33382A (es) 2011-10-31
KR101564806B1 (ko) 2015-10-30
JP5702855B2 (ja) 2015-04-15
US20140213572A1 (en) 2014-07-31
IL222898A0 (en) 2012-12-31
TW201206902A (en) 2012-02-16
US20160102075A1 (en) 2016-04-14
CN103221404B (zh) 2015-12-16
AU2011253057A1 (en) 2012-11-29
US9718803B2 (en) 2017-08-01
CN103221404A (zh) 2013-07-24
NZ603876A (en) 2015-02-27
CA2798490A1 (en) 2011-11-17
MA34300B1 (fr) 2013-06-01
SG185515A1 (en) 2012-12-28
ZA201208510B (en) 2017-11-29
UA109438C2 (uk) 2015-08-25
CL2012003178A1 (es) 2013-07-05
AU2011253057B2 (en) 2014-11-20
EA201291236A1 (ru) 2013-11-29
US20110306587A1 (en) 2011-12-15
PE20130576A1 (es) 2013-05-19
JP2013526536A (ja) 2013-06-24
BR112012029026A2 (pt) 2016-08-02
CO6630189A2 (es) 2013-03-01
KR20130065666A (ko) 2013-06-19

Similar Documents

Publication Publication Date Title
TN2012000530A1 (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
TN2011000220A1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
CA2871471C (en) Dna-pk inhibitors
TN2010000167A1 (en) Organic compounds
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2013004491A (es) Boronatos como inhibidores de arginasa.
ZA201000079B (en) Organic compounds
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MY153915A (en) Organic compounds
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
MX2010007392A (es) Antagonistas de trpa1.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX2010009837A (es) Tiazolil-dihidro-indazoles.
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
GB2469980A (en) Novel napthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors
DE602007008947D1 (en) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3-modulatoren
TN2010000488A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors